Report Hub
Airfinity's independent intelligence is frequently quoted and shared by decision makers around the world. Below you will find all of the currently available reports and forecasts.
If you would like to get access to the latest analysis and data, book a demo today.
COVID-19 Antiviral Pills Revenue Forecast
Published by Airfinity
Airfinity has released its latest COVID-19 treatments revenue forecast for Q1 2022 and 2022. The forecast increases its total sales estimate for the year from $19.5bn to $32.5bn.
Read more
COVID-19 Vaccine Market Revenue Forecast 2022
Published by Airfinity
Airfinity has downgraded its global sales forecast for COVID-19 vaccines this year from $80.8bn to $64.1bn.
Next Generation Lipid Lowering Therapeutics: 2021 in Review
Published by Airfinity
Which candidates accrued the highest SSoV across all lipid lowering therapies in 2021? What topics were KOLs most engaged with and what implications does that have for the market?
Download a sample of our analysis for free today.
COVID-19 Intel Report: December 2021
Published by Airfinity
Dec 16, 2021
Airfinity’s COVID-19 Intel Report covers the COVID-19 vaccine market, including 2021 production, country-level vaccination coverage, Omicron-targeted candidate forecasts and what innovation 2022 will bring.